Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AstraZeneca's ALXN-2220?
ALXN-2220 is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Amyloid Cardiomyopathy. According to Globaldata,...
ALXN-2220 by Alexion Pharmaceuticals for Familial Amyloid Cardiomyopathy: Likelihood of Approval
ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Familial Amyloid Cardiomyopathy. According to GlobalData,...
ALXN-2220 by Alexion Pharmaceuticals for Amyloid Cardiomyopathy: Likelihood of Approval
ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Amyloid Cardiomyopathy. According to GlobalData, Phase...